uhs pharmacy limited
uhs pharmacy limited Company Information
Company Number
08206912
Next Accounts
Dec 2025
Industry
Dispensing chemist in specialised stores
Shareholders
university hospital southampton nhs foundation trust
Group Structure
View All
Contact
Registered Address
trust management offices mailpoi, southampton general hospital, southampton, hampshire, SO16 6YD
Website
uhshospitalpharmacy.co.ukuhs pharmacy limited Estimated Valuation
Pomanda estimates the enterprise value of UHS PHARMACY LIMITED at £7.1m based on a Turnover of £23.7m and 0.3x industry multiple (adjusted for size and gross margin).
uhs pharmacy limited Estimated Valuation
Pomanda estimates the enterprise value of UHS PHARMACY LIMITED at £2.2m based on an EBITDA of £610k and a 3.53x industry multiple (adjusted for size and gross margin).
uhs pharmacy limited Estimated Valuation
Pomanda estimates the enterprise value of UHS PHARMACY LIMITED at £4.9m based on Net Assets of £2.3m and 2.13x industry multiple (adjusted for liquidity).
Edit your figures and get a professional valuation report.
Uhs Pharmacy Limited Overview
Uhs Pharmacy Limited is a live company located in southampton, SO16 6YD with a Companies House number of 08206912. It operates in the dispensing chemist in specialised stores sector, SIC Code 47730. Founded in September 2012, it's largest shareholder is university hospital southampton nhs foundation trust with a 100% stake. Uhs Pharmacy Limited is a established, large sized company, Pomanda has estimated its turnover at £23.7m with healthy growth in recent years.
Upgrade for unlimited company reports & a free credit check
Uhs Pharmacy Limited Health Check
Pomanda's financial health check has awarded Uhs Pharmacy Limited a 4 rating. We use a traffic light system to show it exceeds the industry average on 4 measures and has 5 areas for improvement. Company Health Check FAQs
4 Strong
2 Regular
5 Weak
Size
annual sales of £23.7m, make it larger than the average company (£12.6m)
£23.7m - Uhs Pharmacy Limited
£12.6m - Industry AVG
Growth
3 year (CAGR) sales growth of 7%, show it is growing at a similar rate (7.1%)
7% - Uhs Pharmacy Limited
7.1% - Industry AVG
Production
with a gross margin of 7.1%, this company has a higher cost of product (31.9%)
7.1% - Uhs Pharmacy Limited
31.9% - Industry AVG
Profitability
an operating margin of 2.3% make it as profitable than the average company (2.6%)
2.3% - Uhs Pharmacy Limited
2.6% - Industry AVG
Employees
with 21 employees, this is below the industry average (62)
21 - Uhs Pharmacy Limited
62 - Industry AVG
Pay Structure
on an average salary of £49.6k, the company has a higher pay structure (£28.1k)
£49.6k - Uhs Pharmacy Limited
£28.1k - Industry AVG
Efficiency
resulting in sales per employee of £1.1m, this is more efficient (£145.3k)
£1.1m - Uhs Pharmacy Limited
£145.3k - Industry AVG
Debtor Days
There is insufficient data available for this Key Performance Indicator!
- - Uhs Pharmacy Limited
- - Industry AVG
Creditor Days
its suppliers are paid after 24 days, this is quicker than average (64 days)
24 days - Uhs Pharmacy Limited
64 days - Industry AVG
Stock Days
it holds stock equivalent to 22 days, this is less than average (32 days)
22 days - Uhs Pharmacy Limited
32 days - Industry AVG
Cash Balance
has cash to cover current liabilities for 0 weeks, this is less cash available to meet short term requirements (14 weeks)
0 weeks - Uhs Pharmacy Limited
14 weeks - Industry AVG
Debt Level
it has a ratio of liabilities to total assets of 50.7%, this is a lower level of debt than the average (59.1%)
50.7% - Uhs Pharmacy Limited
59.1% - Industry AVG
UHS PHARMACY LIMITED financials
Uhs Pharmacy Limited's latest turnover from March 2024 is £23.7 million and the company has net assets of £2.3 million. According to their latest financial statements, Uhs Pharmacy Limited has 21 employees and maintains cash reserves of £9 thousand as reported in the balance sheet.
Data source: Companies House, Pomanda Estimates
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Turnover | 23,733,000 | 24,023,000 | 23,544,000 | 19,154,000 | 16,426,000 | 14,534,000 | 14,324,000 | 13,265,000 | 12,462,000 | 9,763,000 | ||
| Other Income Or Grants | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Cost Of Sales | 22,040,000 | 22,092,000 | 22,114,000 | 18,107,000 | 15,834,000 | 13,793,000 | 13,548,000 | 12,507,000 | 11,743,000 | 9,119,000 | ||
| Gross Profit | 1,693,000 | 1,931,000 | 1,430,000 | 1,047,000 | 592,000 | 741,000 | 776,000 | 758,000 | 719,000 | 644,000 | ||
| Admin Expenses | 1,146,000 | 1,047,000 | 887,000 | 741,000 | 700,000 | 539,000 | 449,000 | 446,000 | 715,000 | 618,000 | ||
| Operating Profit | 547,000 | 884,000 | 543,000 | 306,000 | -108,000 | 202,000 | 327,000 | 312,000 | 4,000 | 26,000 | ||
| Interest Payable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Interest Receivable | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17,000 | ||
| Pre-Tax Profit | 547,000 | 884,000 | 543,000 | 306,000 | -108,000 | 202,000 | 277,000 | 2,000 | 4,000 | 9,000 | ||
| Tax | -5,000 | -109,000 | -98,000 | -273,000 | -2,000 | -34,000 | 0 | 0 | 0 | 0 | ||
| Profit After Tax | 542,000 | 775,000 | 445,000 | 33,000 | -110,000 | 168,000 | 277,000 | 2,000 | 4,000 | 9,000 | ||
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||
| Retained Profit | 542,000 | 775,000 | 445,000 | 33,000 | -110,000 | 168,000 | 277,000 | 2,000 | 4,000 | 9,000 | ||
| Employee Costs | 1,042,000 | 800,000 | 748,000 | 563,000 | 591,000 | 393,000 | 337,000 | 316,000 | 286,000 | 256,000 | ||
| Number Of Employees | 21 | 24 | 17 | 18 | 18 | 14 | 12 | 11 | 11 | 9 | ||
| EBITDA* | 610,000 | 899,000 | 582,000 | 351,000 | -68,000 | 236,000 | 360,000 | 345,000 | 30,000 | 25,822,000 |
* Earnings Before Interest, Tax, Depreciation and Amortisation
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Tangible Assets | 331,000 | 383,000 | 45,000 | 80,000 | 127,000 | 85,000 | 82,000 | 100,000 | 129,000 | 104,000 | 129,451 | 0 |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Investments & Other | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Debtors (Due After 1 year) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Total Fixed Assets | 331,000 | 383,000 | 45,000 | 80,000 | 127,000 | 85,000 | 82,000 | 100,000 | 129,000 | 104,000 | 129,451 | 0 |
| Stock & work in progress | 1,345,000 | 1,288,000 | 1,837,000 | 819,000 | 840,000 | 816,000 | 594,000 | 481,000 | 480,000 | 429,000 | 546,219 | 0 |
| Trade Debtors | 0 | 12,000 | 18,000 | 7,000 | 1,319,000 | 12,000 | 6,000 | 2,000 | 0 | 0 | 752,896 | 0 |
| Group Debtors | 2,546,000 | 399,000 | 686,000 | 684,000 | 121,000 | 2,000 | 141,000 | 0 | 1,385,000 | 1,093,000 | 0 | 0 |
| Misc Debtors | 397,000 | 350,000 | 508,000 | 304,000 | 279,000 | 502,000 | 485,000 | 310,000 | 340,000 | 319,000 | 0 | 0 |
| Cash | 9,000 | 1,845,000 | 210,000 | 1,146,000 | 43,000 | 1,219,000 | 905,000 | 1,031,000 | 9,000 | 20,000 | 56,048 | 0 |
| misc current assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total current assets | 4,297,000 | 3,894,000 | 3,259,000 | 2,960,000 | 2,602,000 | 2,551,000 | 2,131,000 | 1,824,000 | 2,214,000 | 1,861,000 | 1,355,163 | 0 |
| total assets | 4,628,000 | 4,277,000 | 3,304,000 | 3,040,000 | 2,729,000 | 2,636,000 | 2,213,000 | 1,924,000 | 2,343,000 | 1,965,000 | 1,484,614 | 0 |
| Bank overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Bank loan | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Trade Creditors | 1,506,000 | 1,147,000 | 1,755,000 | 1,534,000 | 1,535,000 | 702,000 | 1,081,000 | 1,071,000 | 1,493,000 | 1,119,000 | 1,283,038 | 58,040 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | 0 | 640,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| other short term finances | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other current liabilities | 839,000 | 1,389,000 | 183,000 | 290,000 | 11,000 | 1,000 | 7,000 | 5,000 | 4,000 | 4,000 | 0 | 0 |
| total current liabilities | 2,345,000 | 2,536,000 | 1,938,000 | 1,824,000 | 1,546,000 | 1,343,000 | 1,088,000 | 1,076,000 | 1,497,000 | 1,123,000 | 1,283,038 | 58,040 |
| loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| hp & lease commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Accruals and Deferred Income | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 210,000 | 0 |
| provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| total long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 210,000 | 0 |
| total liabilities | 2,345,000 | 2,536,000 | 1,938,000 | 1,824,000 | 1,546,000 | 1,343,000 | 1,088,000 | 1,076,000 | 1,497,000 | 1,123,000 | 1,493,038 | 58,040 |
| net assets | 2,283,000 | 1,741,000 | 1,366,000 | 1,216,000 | 1,183,000 | 1,293,000 | 1,125,000 | 848,000 | 846,000 | 842,000 | -8,424 | -58,040 |
| total shareholders funds | 2,283,000 | 1,741,000 | 1,366,000 | 1,216,000 | 1,183,000 | 1,293,000 | 1,125,000 | 848,000 | 846,000 | 842,000 | -8,424 | -58,040 |
| Mar 2024 | Mar 2023 | Mar 2022 | Mar 2021 | Mar 2020 | Mar 2019 | Mar 2018 | Mar 2017 | Mar 2016 | Mar 2015 | Mar 2014 | Mar 2013 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||
| Operating Profit | 547,000 | 884,000 | 543,000 | 306,000 | -108,000 | 202,000 | 327,000 | 312,000 | 4,000 | 26,000 | ||
| Depreciation | 63,000 | 15,000 | 39,000 | 45,000 | 40,000 | 34,000 | 33,000 | 33,000 | 26,000 | 25,796,000 | 15,861 | 0 |
| Amortisation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Tax | -5,000 | -109,000 | -98,000 | -273,000 | -2,000 | -34,000 | 0 | 0 | 0 | 0 | ||
| Stock | 57,000 | -549,000 | 1,018,000 | -21,000 | 24,000 | 222,000 | 113,000 | 1,000 | 51,000 | -117,219 | 546,219 | 0 |
| Debtors | 2,182,000 | -451,000 | 217,000 | -724,000 | 1,203,000 | -116,000 | 320,000 | -1,413,000 | 313,000 | 659,104 | 752,896 | 0 |
| Creditors | 359,000 | -608,000 | 221,000 | -1,000 | 833,000 | -379,000 | 10,000 | -422,000 | 374,000 | -164,038 | 1,224,998 | 58,040 |
| Accruals and Deferred Income | -550,000 | 1,206,000 | -107,000 | 279,000 | 10,000 | -6,000 | 2,000 | 1,000 | 0 | 4,000 | 0 | 0 |
| Deferred Taxes & Provisions | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Cash flow from operations | -1,825,000 | 2,388,000 | -637,000 | 1,101,000 | -454,000 | -289,000 | -61,000 | 1,336,000 | 40,000 | 25,120,077 | ||
| Investing Activities | ||||||||||||
| capital expenditure | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4,000 | -51,000 | 0 | ||
| Change in Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| cash flow from investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -4,000 | -51,000 | 0 | ||
| Financing Activities | ||||||||||||
| Bank loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Group/Directors Accounts | 0 | 0 | 0 | 0 | -640,000 | 640,000 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Short Term Loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Long term loans | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Hire Purchase and Lease Commitments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| other long term liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -210,000 | 210,000 | 0 |
| share issue | ||||||||||||
| interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 17,000 | ||
| cash flow from financing | 0 | -400,000 | -295,000 | 0 | -640,000 | 640,000 | 0 | 0 | 0 | 648,424 | ||
| cash and cash equivalents | ||||||||||||
| cash | -1,836,000 | 1,635,000 | -936,000 | 1,103,000 | -1,176,000 | 314,000 | -126,000 | 1,022,000 | -11,000 | -36,048 | 56,048 | 0 |
| overdraft | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| change in cash | -1,836,000 | 1,635,000 | -936,000 | 1,103,000 | -1,176,000 | 314,000 | -126,000 | 1,022,000 | -11,000 | -36,048 | 56,048 | 0 |
uhs pharmacy limited Credit Report and Business Information
Uhs Pharmacy Limited Competitor Analysis
Perform a competitor analysis for uhs pharmacy limited by selecting its closest rivals, whether from the WHOLESALE AND RETAIL TRADE; REPAIR OF MOTOR VEHICLES AND MOTORCYCLES sector, other large companies, companies in SO16 area or any other competitors across 12 key performance metrics.
uhs pharmacy limited Ownership
UHS PHARMACY LIMITED group structure
Uhs Pharmacy Limited has no subsidiary companies.
Ultimate parent company
UNIVERSITY HOSPITAL SOUTHAMPTON NHS
#0102140
1 parent
UHS PHARMACY LIMITED
08206912
uhs pharmacy limited directors
Uhs Pharmacy Limited currently has 7 directors. The longest serving directors include Mr Gary Anderson (Nov 2019) and Dr Julia Pendred (Jul 2020).
| officer | country | age | start | end | role |
|---|---|---|---|---|---|
| Mr Gary Anderson | England | 63 years | Nov 2019 | - | Director |
| Dr Julia Pendred | 46 years | Jul 2020 | - | Director | |
| Ms Felicity Greene | England | 59 years | Jul 2020 | - | Director |
| Dr Julia Pendred | 46 years | Jul 2020 | - | Director | |
| Mr Paul Grundy | 56 years | Feb 2021 | - | Director | |
| Mr Philip Bunting | 41 years | Apr 2023 | - | Director | |
| Modupe Olorunfemi | 49 years | Apr 2024 | - | Director |
P&L
March 2024turnover
23.7m
-1%
operating profit
547k
-38%
gross margin
7.2%
-11.25%
turnover
Turnover, or revenue, is the amount of sales generated by a company within the financial year.
Balance Sheet
March 2024net assets
2.3m
+0.31%
total assets
4.6m
+0.08%
cash
9k
-1%
net assets
Total assets minus all liabilities
uhs pharmacy limited company details
company number
08206912
Type
Private limited with Share Capital
industry
47730 - Dispensing chemist in specialised stores
incorporation date
September 2012
age
12
incorporated
UK
ultimate parent company
accounts
Small Company
last accounts submitted
March 2024
previous names
N/A
accountant
-
auditor
KRESTON REEVES LLP
address
trust management offices mailpoi, southampton general hospital, southampton, hampshire, SO16 6YD
Bank
-
Legal Advisor
-
uhs pharmacy limited Charges & Mortgages
A charge, or mortgage, refers to the rights a company gives to a lender in return for a loan, often in the form of security given over business assets.
We did not find charges/mortgages relating to uhs pharmacy limited.
uhs pharmacy limited Capital Raised & Share Issues BETA
When a company issues new shares, e.g. to new investors following a funding round, it is required to notify Companies House within one month of making an allotment of shares.
Click to start generating capital raising & share issue transactions for UHS PHARMACY LIMITED. This can take several minutes, an email will notify you when this has completed.
uhs pharmacy limited Companies House Filings - See Documents
| date | description | view/download |
|---|
